MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...
ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback